Company profilePharmaceutical#818 of 1,318 in Pakistan✓ No DRAP alerts

GSK Pakistan Limited DSL: 066

Pharmaceutical company · 9 brands · 14 molecules

9 registered products 12 pharmaceutical brands 14 distinct molecules 0 DRAP alerts

Company overview

9
registered products
12
pharmaceutical brands
14
distinct molecules
0
therapeutic classes
0
DRAP alerts

GSK Pakistan Limited DSL: 066 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 9 product registrations across 14 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by GSK

10 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

7
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20267

Top molecules by brand count

Human Papillomavirus Vaccine Type 16 L 1 Protein 16 ...... 20 Mcg1 brand
23F1 brand
18C1 brand
19F ...... 0.5 Ml1 brand
Salbutamol ...... 100 Mcg1 brand
Live Attenuated Varicella Virus Oka Strain ...... 10^3.3 Pfu1 brand
Live Attenuated Measles Virus ...... Not Less Than 10^3.0 Ccid 501 brand
Pertussis Toxoid ...... 8 Mcg (Absorbed On Alu1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official9 products · Rs 413.07 – Rs 57,906.24
Median across source: Rs 4,357.97

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GSK Pakistan Limited holds 19 molecules not in this portfolio
BacitracinBenzoyl PeroxideBetamethasoneClindamycinClindamycin TopicalClobetasol
AGP (PRIVATE) LTD. holds 142 molecules not in this portfolio
AmikacinAminophyllineAmlodipineAmoxicillinAprepitantArtemether
SEARLE PAKISTAN (PVT.) LTD. holds 237 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline

Get the full profile for GSK

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.